Pegfilgrastim

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Peripheral Blood Stem Cell Transplantation

Conditions

Peripheral Blood Stem Cell Transplantation

Trial Timeline

May 28, 2019 → Aug 28, 2020

NCT ID

NCT03993639

About Pegfilgrastim

Pegfilgrastim is a phase 2 stage product being developed by Kyowa Kirin for Peripheral Blood Stem Cell Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT03993639. Target conditions include Peripheral Blood Stem Cell Transplantation.

What happened to similar drugs?

20 of 20 similar drugs in Peripheral Blood Stem Cell Transplantation were approved

Approved (20) Terminated (4) Active (0)

✅Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved

✅Anplag Tab. 100mg bid + Anplag Tab. 100mg tidYuhanApproved

✅QUTENZA + Lidocaine + TramadolAstellas PharmaApproved

✅Qutenza + PregabalinAstellas PharmaApproved

✅Duloxetine + Pregabalin + PlaceboShionogiApproved

✅Mecobalamin IV Injection + Mecobalamin IM injection + Mecobalamin IV or IM injectionEisaiApproved

✅Ticagrelor + clopidogrelAstraZenecaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03993639	Phase 2	Completed	May 28, 2019	Aug 28, 2020	Peripheral Blood Stem Cell Transplantation
NCT00364468	Phase 2	Completed	Mar 1, 2006	Mar 1, 2008	Neutropenia

Competing Products

20 competing products in Peripheral Blood Stem Cell Transplantation

See all competitors

Product	Company	Stage	Hype Score
SON-080	Sonnet BioTherapeutics	Phase 1/2	18
LY3857210 + Placebo	Eli Lilly	Phase 2	35
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mg	Yuhan	Approved	43
YHD1119 + Lyrica	Yuhan	Phase 1	29
Anplag Tab. 100mg bid + Anplag Tab. 100mg tid	Yuhan	Approved	43
YHD1119 + Lyrica	Yuhan	Phase 1	29
YHD1119 + Lyrica	Yuhan	Phase 3	40
YHD1119 300mg + YHD1119 300mg	Yuhan	Phase 1	29
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsule	Daiichi Sankyo	Phase 2	35
edoxaban + Clopidogrel + Aspirin	Daiichi Sankyo	Phase 2	35
DS-5565 + placebo	Daiichi Sankyo	Phase 3	40
Mirogabalin + Placebo	Daiichi Sankyo	Phase 3	40
DS-5565	Daiichi Sankyo	Phase 3	40
Valemetostat Tosylate	Daiichi Sankyo	Phase 2	39
ASP3662 + pregabalin + ASP3662 placebo + pregabalin placebo	Astellas Pharma	Phase 2	27
Qutenza	Astellas Pharma	Pre-clinical	26
QUTENZA + Lidocaine + Tramadol	Astellas Pharma	Approved	43
Qutenza exposure	Astellas Pharma	Pre-clinical	26
QUTENZA	Astellas Pharma	Phase 3	40
Qutenza + Pregabalin	Astellas Pharma	Approved	43